Daily News Podcast

Empagliflozin and left ventricular mass


 

Empagliflozin significantly reduced left ventricular mass over the course of 6 months in patients who have type 2 diabetes and with stable coronary artery disease. Also today, symptomatic hyperuricemia may respond to urate-lowering therapy, the risk for cancer in non-alcoholic fatty liver disease is 91% higher than the general population, the link between antibiotic use and obesity is insignificant at age 10.

Amazon Alexa
Apple Podcasts
Google Podcasts
Spotify

Recommended Reading

‘Organoid technology’ poised to transform cancer care
MDedge Internal Medicine
Heart failure and sacubiril/valsartan
MDedge Internal Medicine
Vitamin D, fish out, and primary prevention
MDedge Internal Medicine
December 2018
MDedge Internal Medicine
USPSTF: screen for ‘unhealthy’ alcohol use
MDedge Internal Medicine
Obesity curbs decades of CVD progress
MDedge Internal Medicine
AHA 2018: Part I
MDedge Internal Medicine
Physical fitness guidelines from HHS
MDedge Internal Medicine
Novel formulation for childhood ADHD
MDedge Internal Medicine
AHA 2018: Part II
MDedge Internal Medicine